Connecting the Dots in Antipsychotic Maintenance Therapy
neuroscienceCME Live and On DemandPremiere Date: Wednesday, October 5, 2011
This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Psychologists (APA)
- Social Workers (NASW)
- Certified Case Managers (CCMC)
- Pharmacists (ACPE)
All other clinicians will either receive a CME Attendance Certificate or may choose any of the types of CE credit being offered.
Credit Expiration Date:
Friday, October 5, 2012
|Henry A. Nasrallah, MD (Moderator)
Professor of Psychiatry and Neuroscience
University of Cincinnati College of Medicine
|Leslie Citrome, MD, MPH
Adjunct Professor of Psychiatry & Behavioral Sciences
New York Medical College
|Diana O. Perkins, MD, MPH
Professor, Department of Psychiatry
Medical Director, Outreach and Support Intervention Services (OASIS)
University of North Carolina
Chapel Hill, NC
Medication nonadherence is common and difficult to detect in patients with schizophrenia. Roughly 50% of patients take less than 70% of prescribed doses. Clinical management requires getting the patient on the most appropriate medication, working with patients and families to improve adherence to medication, and then consistently measuring efficacy and side effects. Many factors contribute to nonadherence, including poor illness insight, a negative attitude toward medication, and adverse events such as weight gain or metabolic changes.(1) Clinicians who establish functional partnerships with their patients are able to deliver messages in a way that they are heard. Messaging includes emphasis on the necessity of medication adherence to prevent relapse during the maintenance phase, and the importance of using measurement-based care during all phases of treatment for schizophrenia.(2)
This neuroscienceCME Live and On Demand activity will support clinicians to become increasingly proactive in managing adherence and in monitoring their patients with schizophrenia for both clinical progress and optimal outcome.
- Goff DC, Hill M, Freudenreich O. Treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2011;72(4):e13. PMID: 21527119.
- Kane JM. Transitioning from acute to long-term treatment in schizophrenia. J Clin Psychiatry. 2011;72(3):e10. PMID: 21450146.
To implement actionable strategies to integrate measurement-based care and improve adherence to antipsychotic medications.
At the end of this CE activity, participants should be able to:
- Define the critical areas that affect nonadherence to antipsychotic medication and implement strategies to address adherence in patients with schizophrenia.
- Review the available tools to evaluate patients' progress and implement regular, measurement-based evaluations.
- Implement regular metabolic screening for patients taking antipsychotic medication.
The following learning objectives pertain only to those requesting CNE credit:
- Review the critical areas that affect nonadherence to antipsychotic medication and define strategies to address adherence.
- Describe the available measurement-based tools to evaluate patients' progress that can be used regularly in practice.
- Recognize the necessity for regular metabolic screening for patients taking antipsychotic medication.
Physicians, physician assistants, nurses, nurse practitioners, pharmacists, psychologists, social workers, certified case managers, and other nonphysician health care professionals with an interest in schizophrenia.
USF Health and CME Outfitters, LLC, gratefully acknowledge an educational grant from Genentech in support of this CE activity. This activity is supported by an educational grant from Lilly, USA, LLC. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
CME Credit (Physicians):
USF Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to Physician Assistants: AAPA accepts Category I credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.0 contact hour.
CEP Credit (Psychologists):
CME Outfitters is approved by the American Psychological Association to sponsor continuing education for psychologists. CME Outfitters maintains responsibility for this program and its content. (1.0 CE credits)
NASW Credit (Social Workers):
This program was approved by the National Association of Social Workers (provider #886407722) for 1.0 continuing education contact hour.
CCMC Credit (Certified Case Managers):
This program has been approved for 1 hour by the Commission for Case Manager Certification (CCMC).
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.0 contact hours (0.1 CEUs)
Universal Activity Number: 0376-9999-11-019-H01-P (recorded programs)
Activity Type: knowledge-based
For CME questions or comments, please contact: USF Health at firstname.lastname@example.org.
Disclosure of Relevant Financial Relationships with Commercial Interests
USF Health and CME Outfitters, LLC, adhere to the ACCME Standards, as well as those of the ACPE, APA, and ANCC, regarding commercial support of continuing medical education. It is the policy of USF Health and CME Outfitters, LLC, that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved, and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.
A conflict of interest is created when individuals in a position to control the content of CME have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.
USF Health and CME Outfitters will identify, review, and resolve all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Relevant financial relationships exist between the following individuals and commercial interests:
Dr. Nasrallah has disclosed that he receives grants/research support from Forest Laboratories, Inc.; Genentech; Roche; Otsuka America Pharmaceutical Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; and Shire Pharmaceuticals. He serves on the advisory board and as a consultant to AstraZeneca Pharmacueticals; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Norvartis Corporation; Pfizer Inc.; Roche; Shire Pharmaceuticals; and Sunovion Pharmaceuticals Inc. He serves on the speakers bureau of AstraZeneca Pharmacueticals; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Norvartis Corporation; Pfizer Inc.; and Sunovion Pharmaceuticals Inc.
Dr. Citrome has disclosed that he receives grants/research support from AstraZeneca; Pfizer Inc.; and Sunovion Pharmaceuticals Inc. He serves as a consultant to Bristol-Myers Squibb; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Novartis Corporation; Noven Pharmaceuticals, Inc.; Pfizer Inc.; Shire Pharmaceuticals; Sunovion Pharmaceuticals Inc.; and Valeant. He is a stock/shareholder (self-managed) of Bristol-Myers Squibb; Eli Lilly and Company; Johnson & Johnson; Merck & Co.; Pfizer Inc.; Cardinal Health; and Medco Health Solutions.
Dr. Perkins has disclosed that she serves on the advisory board of Genentech, Inc.; and Merck & Co., Inc. She serves as a consultant to Eli Lilly and Company; Endo Pharmaceuticals; and Sunovion Pharmaceuticals Inc. She is on the speakers bureau of Eli Lilly and Company
Disclosures were obtained from the planning committee members and are on file in the USF Health Office of Continuing Professional Development (OCPD) for review. Disclosures were obtained from the USF Health OCPD staff: Nothing to Disclose.
Howard Bliwise, MD (content/peer reviewer) has no disclosures to report.
Nancy Jennings, MSN, MBA, MHA, RNC (content/peer reviewer) has no disclosures to report.
Ruth Cody, BSN, RN-BC (content/peer reviewer) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
Robert Kennedy (planning committee) has no disclosures to report.
Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
USF Health, CME Outfitters, LLC, the faculty, Genentech and Lilly, USA, LLC do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Equal Opportunity Statement: Events, activities, programs and facilities of the University of South Florida are available to all without regard to race, color, marital status, gender, sexual orientation, religion, national origin, disability, age, Vietnam or disabled veteran status as provided by law and in accordance with the university’s respect for personal dignity.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).